Sat Oct 25 00:30:00 UTC 2025: Okay, here’s a summary and a rewritten news article based on the provided text:

Summary:

Google’s DeepMind has unveiled “C2S-Scale,” an AI model built on the Gemma family, designed to analyze cellular molecular data. This AI successfully identified a potential new use for the drug silmitasertib in cancer therapy, which has been validated in early lab tests. While not a revolutionary discovery, the AI’s ability to sift through vast amounts of data and suggest a novel drug application highlights the potential of AI in accelerating scientific discovery. Indian scientists, including those at the Institute for Stem Cell Science and Regenerative Medicine and the Indian Institute of Science, acknowledge the promise of AI in research, but also stress that current AI capabilities are not yet at “genius-human levels.” The findings suggest AI can be a powerful tool for researchers, although widespread adoption is still debated within the scientific community. Some are also looking into AI’s potential to solve complex mathematical problems, such as the Riemann Hypothesis.

News Article:

AI Breakthrough: Google’s “C2S-Scale” Identifies Novel Cancer Therapy Approach

Bangalore, October 25, 2025 – Google DeepMind has unveiled a new artificial intelligence (AI) model, “C2S-Scale,” that has successfully identified a potential new use for an existing drug in cancer therapy. The model, built on the Gemma family and designed to interpret the “language” of cells, suggested that silmitasertib could enhance the immune system’s ability to target nascent cancerous tumors. Early laboratory tests have validated this prediction.

“This announcement marks a milestone for AI in science,” stated Shekoofeh Azizi and Brian Perozzi, staff scientists at Google DeepMind and Google Research, in a press release. “C2S-Scale generated a novel hypothesis about cancer cellular behaviour and we have since confirmed its prediction with experimental validation in living cells. This discovery reveals a promising new pathway for developing therapies to fight cancer.”

Silmitasertib is already in clinical trials for other conditions, but the AI’s ability to scan the extensive body of cancer research and propose a new application is noteworthy. Experts estimate this could significantly speed up drug discovery processes that typically cost billions of dollars and countless man-hours.

“It’s a nice result,” commented Sunil Laxman, a systems biologist at the Institute for Stem Cell Science and Regenerative Medicine in Bengaluru. “This would, in the usual course, have taken a focused team of dedicated researchers several months to suggest such a use of the drug.” However, Dr. Laxman noted that the AI had not discovered anything fundamentally new about cancer, and its capabilities are contingent on access to extensive databases and testing resources.

Siddhartha Gadgil, a mathematics professor at the Indian Institute of Science, believes the findings are significant, drawing parallels to AI’s growing capabilities in mathematics. He suggests that AI could one day solve even the most challenging mathematical problems, such as the Riemann Hypothesis, for which a $1 million prize is offered.

While AI’s potential in scientific research is gaining recognition, its widespread adoption faces some resistance within the scientific community. The debate centers on whether AI should be embraced as a powerful tool, that can accelerate the process of discovery or just a helpful assistant. Some experts highlight limitations regarding the availability of data, as well as the means for testing the AI’s proposed solutions.

Despite these considerations, the “C2S-Scale” success underscores the transformative potential of AI to drive advancements in medicine and beyond. The Hindu On Books section has been updated to include information about the new AI and is available now.

Read More